Immunizing against risk

Although Emergent BioSolutions Inc. has been a major beneficiary of U.S. government demand for biodefense products, the company decided it needed to broaden both its future investor appeal and its commercial vaccines portfolio. It didn't have far to look to home in on Microscience Ltd., a British vaccine technology and development company. This is because Steven Chatfield and Jonathan Pockson, Emergent's CSO and CFO, held the exact same positions in the British company just 18 months ago.

While Emergent expects to post revenues of more than $100 million this year from

Read the full 905 word article

How to gain access

Continue reading with a
two-week free trial.